Abbvie to record $3.5 bln charge related to schizophrenia drug
Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
Pfizer's bladder cancer therapy meets main goal in late-stage study
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
BioSpace1h
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...
Pfizer's Sasanlimab Hits Late-Stage Study Primary Endpoint for Bladder Cancer
Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...
Alzheimer’s could be diagnosed 10 years earlier after world’s largest blood proteins study
Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...
The CEOs Who Are Tearing Up the Policies Trump Hates
Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...
Guillain-Barre Syndrome explained as 2 RSV vaccines flag neurological 'risk'
As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...
RSV vaccines to carry neurological disorder risk warning after new research
On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...
ViewusGlobal on MSN5h
Canadian Teen Breast Size Grows 4x After Pfizer Vaccine: Medical Mystery Explained
A Canadian teen's breasts grew fourfold after receiving the Pfizer COVID-19 vaccine, raising concerns about a rare condition ...
FierceBiotech2h
Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...
FiercePharma1h
FDA cancels adcomm in 'positive' sign for Exelixis’ Cabometyx bid in neuroendocrine tumors: analyst
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors at an advisory committee meeting. | On second thought, the FDA figures it ...